Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.

Abstract

Marginal zone lymphoma (MZL) belongs to the group of indolent B-cell non-Hodgkin's lymphomas, which is characterized by an indolent course. In this mostly elderly patient population, the development of chemotherapy-free approaches is of particular interest. In this situation, single-agent treatment with the next-generation anti-CD20 antibody obinutuzumab is an attractive approach, which promises high efficacy without major toxicity. We describe here an open-label, multicentric Phase II trial evaluating the efficacy and safety of obinutuzumab in de novo MZL patients, who are treatment naive for systemic therapy and not eligible for or failed local treatment. ClinicalTrials.gov identifier NCT03322865.

• Authors: Alexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, Birgit Schmelzle, Andreas Viardot, Peter Möller, Thomas Fe Barth, Rainer Muche, Jens Dreyhaupt, Christian Buske
• Journal: Future oncology (London, England) (Future Oncol) Vol. 16 Issue 13 Pg. 817-825 (May 2020) ISSN: 1744-8301 [Electronic] England
• PMID: 32223334 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antigens, CD20
• Antineoplastic Agents
• obinutuzumab

Topics

• Adolescent
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antigens, CD20 (immunology)
• Antineoplastic Agents (therapeutic use)
• Female
• Humans
• Lymphoma, B-Cell, Marginal Zone (drug therapy, metabolism)
• Male